14 results on '"Ata, Baris"'
Search Results
2. Endometrioma excision and ovarian reserve; do assessments by antral follicle count and anti-Müllerian hormone yield contradictory results?
- Author
-
Ata, Baris and Urman, Bülent
- Published
- 2014
- Full Text
- View/download PDF
3. Risk factors for ovarian hyperstimulation syndrome: relevance of the number of follicles, serum estradiol levels and the number of oocytes collected
- Author
-
Ata, Baris, Seyhan, Ayse, Polat, Mehtap, Young Son, Weon, Yarali, Hakan, and Dahan, Michael
- Published
- 2013
- Full Text
- View/download PDF
4. Reply: GnRHa trigger and modified luteal support with one bolus of hCG should be used with caution in extreme responder patients
- Author
-
Ata, Baris, Seyhan, Ayse, Polat, Mehtap, Son, Weon Young, Yarali, Hakan, and Dahan, Michael
- Published
- 2013
- Full Text
- View/download PDF
5. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG
- Author
-
Seyhan, Ayse, Ata, Baris, Polat, Mehtap, Son, Weon-Young, Yarali, Hakan, and Dahan, Michael H.
- Published
- 2013
- Full Text
- View/download PDF
6. Prospective assessment of the impact of endometriomas and their removal on ovarian reserve and determinants of the rate of decline in ovarian reserve†
- Author
-
Uncu, Gurkan, Kasapoglu, Isil, Ozerkan, Kemal, Seyhan, Ayse, Oral Yilmaztepe, Arzu, and Ata, Baris
- Published
- 2013
- Full Text
- View/download PDF
7. Outcomes of SARS-CoV-2 infected pregancies after medically assisted reproduction.
- Author
-
Group, The ESHRE COVID-19 Working, Ata, Baris, Gianaroli, Luca, Lundin, Kersti, Mcheik, Saria, Mocanu, Edgar, Rautakallio-Hokkanen, Satu, Tapanainen, Juha S, Vermeulen, Nathalie, Veiga, Anna, and ESHRE COVID-19 Working Group
- Subjects
- *
COVID-19 , *REPRODUCTIVE technology , *STILLBIRTH , *SARS-CoV-2 , *COVID-19 pandemic , *PREGNANCY outcomes - Abstract
Study Question: What is the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on the outcome of a pregnancy after medically assisted reproduction (MAR)?Summary Answer: Our results suggest that MAR pregnancies are not differentially affected by SARS-CoV-2 infection compared to spontaneous pregnancies.What Is Known Already: Information on the effects of coronavirus disease 2019 (COVID-19) on pregnancy after MAR is scarce when women get infected during MAR or early pregnancy, even though such information is vital for informing women seeking pregnancy.Study Design, Size, Duration: Data from SARS-CoV-2 affected MAR pregnancies were collected between May 2020 and June 2021 through a voluntary data collection, organised by the European Society of Human Reproduction and Embryology (ESHRE).Participants/materials, Setting, Methods: All ESHRE members were invited to participate to an online data collection for SARS-CoV-2-infected MAR pregnancies.Main Results and the Role Of Chance: The dataset includes 80 cases from 32 countries, including 67 live births, 10 miscarriages, 2 stillbirths and 1 maternal death. An additional 25pregnancies were ongoing at the time of writing.Limitations, Reasons For Caution: An international data registry based on voluntary contribution can be subject to selective reporting with possible risks of over- or under-estimation.Wider Implications Of the Findings: The current data can be used to guide clinical decisions in the care of women pregnant after MAR, in the context of the COVID-19 pandemic.Study Funding/competing Interest(s): The authors acknowledge the support of ESHRE for the data registry and meetings. J.S.T. reports grants or contracts from Sigrid Juselius Foundation, EU and Helsinki University Hospital Funds, outside the scope of the current work. The other authors declare that they have no conflict of interest.Trial Registration Number: N/A. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
8. Correct assessment and interpretation of results determines the accuracy of any diagnostic test, and PGT-A is no exception.
- Author
-
Ata, Baris, Popovic, Mina, and Fatemi, Human
- Subjects
- *
DIAGNOSIS methods , *ABORTION , *MOSAICISM , *EMBRYO transfer , *HUMAN embryos - Abstract
PGDIS Position statement on chromosome mosaicism and preimplantation aneuploidy testing at the blastocyst statement. Sir, [2] report live births from blastocysts with "abnormal" results, which were previously denied transfer. In the study by [2], after excluding results predicting "mosaicism" and "segmental aberrations", the transfer embryos with uniform whole chromosome aneuploidies, led to a clinical pregnancy loss rate of 100% (5/5 transfers with exclusively full chromosome aneuploid embryos). [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
9. Ultrasound guided embryo transfer does not offer any benefit in clinical outcome: a randomized controlled study
- Author
-
Ata, Baris and Urman, Bulent
- Published
- 2008
10. The calm after the storm: re-starting ART treatments safely in the wake of the COVID-19 pandemic.
- Author
-
Group, The ESHRE COVID-19 Working, Gianaroli, Luca, Ata, Baris, Lundin, Kersti, Rautakallio-Hokkanen, Satu, Tapanainen, Juha S, Vermeulen, Nathalie, Veiga, Anna, Mocanu, Edgar, and ESHRE COVID-19 Working Group
- Subjects
COVID-19 pandemic ,COVID-19 ,SARS-CoV-2 ,PANDEMICS ,REPRODUCTIVE technology - Abstract
The coronavirus disease 2019 (COVID-19) pandemic created a significant impact on medically assisted reproduction (MAR) services. ESHRE decided to mobilize resources in order to collect, analyse, monitor, prepare and disseminate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) knowledge specifically related to ART and early pregnancy. This article presents the impact of the SARS-CoV-2 pandemic focusing on reproductive healthcare. It details the rationale behind the guidance prepared to support MAR services in organizing and managing the re-start of treatments or in case of any future wave of COVID-19 disease. The guidance includes information on patient selection and informed consent, staff and patient triage and testing, adaptation of ART services, treatment planning and code of conduct. The initiatives detailed in this article are not necessarily COVID-specific and such action plans could be applied effectively to manage similar emergency situations in different areas of medicine, in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Luteal granulosa cells from natural cycles are more capable of maintaining their viability, steroidogenic activity and LH receptor expression than those of stimulated IVF cycles.
- Author
-
Bildik, Gamze, Akin, Nazli, Seyhan, Ayse, Esmaeilian, Yashar, Yakin, Kayhan, Keles, Ipek, Balaban, Basak, Ata, Baris, Urman, Bulent, and Oktem, Ozgur
- Subjects
SERINE/THREONINE kinases ,LUTEINIZING hormone releasing hormone agonists ,CYCLES ,VASCULAR endothelial growth factors ,BAX protein ,GRANULOSA cells - Abstract
Study Question: Are there any differences in the molecular characteristics of the luteal granulosa cells (GC) obtained from stimulated versus non-stimulated (natural) IVF cycles that may help explain the defective luteal phase in the former?Summary Answer: Luteal GC of stimulated IVF cycles, particularly those of agonist-triggered antagonist cycles, are less viable ex vivo, express LH receptor and anti-apoptotic genes at lower levels, undergo apoptosis earlier and fail to maintain their estradiol (E2) and progesterone (P4) production in comparison to natural cycle GC.What Is Known Already: Luteal function is defective in stimulated IVF cycles, which necessitates P4 and/or hCG administration (known as luteal phase support) in order to improve clinical pregnancy rates and prevent miscarriage. The luteal phase becomes shorter and menstruation begins earlier than a natural cycle if a pregnancy cannot be achieved, indicative of early demise of corpus luteum (premature luteolysis). Supra-physiological levels of steroids produced by multiple corpora luteae in the stimulated IVF cycles are believed to inhibit LH release directly via negative feedback actions on the hypothalamic-pituitary-ovarian axis resulting in low circulating levels of LH and a defective luteal phase. We hypothesized that some defects in the viability and steroidogenic activity of the luteal GC of the stimulated IVF cycles might contribute to this defective luteal phase in comparison to natural cycle GC. This issue has not been studied in human before.Study Design, Size, Duration: A comparative translational research study of ex vivo and in vitro models of luteal GC recovered from IVF patients undergoing natural versus stimulated IVF cycles was carried out. Luteinized GC were obtained from 154 IVF patients undergoing either natural (n = 22) or stimulated IVF cycles with recombinant FSH and GnRH agonist (long) (n = 44), or antagonist protocol triggered conventionally either with recombinant hCG (n = 46) or with a GnRH agonist (n = 42). GC were maintained in vitro for up to 6 days.Participants/materials, Setting, Methods: Cellular viability (YO-PRO-1 staining), the expression of the steroidogenic enzymes, pro-apoptotic genes [Bcl-2-associated death promoter (BAD), Bcl-2-associated X protein (BAX) and Caspase-3 (CASP3)], anti-apoptotic genes [RAC-alpha serine/threonine-protein kinase (AKT-1) and Bcl-2-like protein 2 (BCL2-L2)], LH receptor, vascular endothelial growth factor (VEGF) (using real-time quantitative PCR at mRNA level and western blot immunoprecipitation assay at protein level) and in vitro E2 and P4 production (electrochemiluminescence immunoassay) were compared in GC among the groups.Main Results and the Role Of Chance: Natural cycle GC were significantly more viable ex vivo (88%) compared to their counterparts of the stimulated IVF cycles (66, 64 and 37% for agonist and antagonist cycles triggered with hCG and GnRH agonist respectively, P < 0.01). They were also more capable of maintaining their vitality in culture compared to their counterparts from the stimulated IVF cycles: at the end of the 6-day culture period, 74% of the cells were still viable whereas only 48, 43 and 22% of the cells from the agonist and antagonist cycles triggered with hCG and agonist respectively, were viable (P < 0.01). The mRNA expression of anti-apoptotic genes (AKT-1 and BCL2-L2) was significantly lower, while that of pro-apoptotic genes (BAD, BAX and CASP3) was significantly higher in the stimulated cycles, particularly in the agonist-triggered antagonist cycles, compared to natural cycle GC (P < 0.01 for long protocol and antagonist hCG trigger, P < 0.001 for agonist trigger). The expression of steroidogenic enzymes (stAR, SCC, 3β-HSD and aromatase) and VEGF was significantly higher in the agonist and hCG-triggered antagonist cycles compared to natural cycle GC. Therefore, in vitro E2 and P4 production in cells from the stimulated IVF cycles was significantly higher than their counterparts obtained from the natural cycles in the first 2 days of culture. However, after Day 2, their viability and hormone production began to decline very rapidly with the most drastic decrease being observed in the agonist-triggered cycles. By contrast, natural cycle GC maintained their viability and produced E2 and P4 in increasing amounts in culture up to 6 days. In vitro P production and the mRNA and protein expression of LH receptor, VEGF and 3β-HSD were most defective in the agonist-triggered antagonist cycles compared to natural and agonist and hCG-triggered antagonist cycles. In vitro hCG treatment of a subset of the cells from the agonist-triggered cycles improved their viability, increased E2 and P4 production in vitro and up-regulated the mRNA expression of anti-apoptotic gene BCL-L2 together with steroidogenic enzymes stAR, SCC, 3B-HSD, LH receptor and VEGF.Large Scale Data: Not applicable.Limitations, Reasons For Caution: The limitations include analysis of luteinized GC only might not reflect the in vivo mechanisms involved in survival and function of the whole corpus luteum; GC recovered during oocyte retrieval belong to a very early stage of the luteal phase and might not be representative; effects of ovulation triggered with hCG may not equate to the endogenous LH trigger; the clinical characteristics of the patients may vary among the different groups and it was not possible to correlate stimulation-related molecular alterations in luteal GC with the clinical outcome, as no oocytes have been utilized yet. Therefore, our findings do not conclusively rule out the possibility that some other mechanisms in vivo may also account for defective luteal function observed in stimulated IVF cycles.Wider Implications Of the Findings: Ovarian stimulation is associated with significant alterations in the viability and steroidogenic activity of luteal GC depending on the stimulation protocol and mode of ovulation trigger. Reduced survival and down-regulated expression of 3B-HSD, LH receptor and VEGF leading to compromised steroid production in stimulated cycles, and particularly in the agonist-triggered cycles, may at least in part help explain why the luteal phase is defective and requires exogenous support in these cycles.Study Funding/competing Interest(s): This study was funded by the School of Medicine, the Graduate School of Health Sciences of Koc University and Koç University Research Center for Translational Medicine (KUTTAM), equally funded by the Republic of Turkey Ministry of Development Research Infrastructure Support Program. All authors declare no conflict of interest. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
12. Which is worse? Comparison of ART outcome between women with primary or recurrent endometriomas.
- Author
-
Ata, Baris, Mumusoglu, Sezcan, Aslan, Kiper, Seyhan, Ayse, Kasapoglu, Isıl, Avcı, Berrin, Urman, Bulent, Bozdag, Gurkan, Uncu, Gurkan, Kasapoglu, Isil, and Avci, Berrin
- Subjects
- *
ENDOMETRIOSIS , *INFERTILITY , *REPRODUCTIVE technology , *CHILDBIRTH , *OVARIAN reserve , *TREATMENT of endometriosis , *INFERTILITY treatment , *ACADEMIC medical centers , *BIRTH rate , *COMPARATIVE studies , *HUMAN reproductive technology , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *SURGICAL complications , *THERAPEUTICS , *DISEASE relapse , *LOGISTIC regression analysis , *EVALUATION research , *RELATIVE medical risk , *RETROSPECTIVE studies , *SEVERITY of illness index ,PREVENTION of surgical complications - Abstract
Study Question: Are live birth rates (LBR) different after ART cycles between women with primary or recurrent endometrioma?Summary Answer: Women with recurrent endometrioma have similar LBR as compared to patients with primary endometrioma.What Is Already Known: Recurrence rate can be as high as 29% after endometrioma excision. Prior studies on management of endometrioma before ART involve primary endometriomas. There is limited information regarding the prognosis of women with recurrent endometriomas.Study Design, Size, Duration: A multicenter retrospective cohort study, including 76 women with primary and 82 women with recurrent endometriomas treated at the participating centers over a 6-year period.Participants/materials, Setting, Methods: Women with endometrioma who underwent ART at three academic ART centers. Couples with another indication for ART were excluded.Main Results and the Role Of Chance: Female age, median number of prior failed ART cycles, proportion of patients with bilateral endometrioma (28 versus 28.9%), ovarian stimulation protocols, and total gonadotropin consumption were similar between the study groups. Numbers of metaphase two oocytes (5 versus 6), number of embryos transferred, and the proportion of patients undergoing blastocyst transfer were similar across the study groups. Clinical pregnancy rates (36.6 versus 34.2%, absolute difference 2.4%, 95% CI: -12.5 to 17.3%, P = 0.83) and LBR (35.4 versus 30.3%, absolute difference 5.1%, 95% CI: -9.5 to 19.7%, P = 0.51) per started cycle in recurrent and primary endometrioma were similar. Comparable success rates were also confirmed with logistic regression analysis (OR: 1.14, 95% CI: 0.78-0.57, P = 2.3).Limitations, Reasons For Caution: The retrospective design has inherent limitations. Some women with severely decreased ovarian reserve after primary endometrioma excision may not have pursued further treatment.Wider Implications Of the Findings: The management of endometrioma prior to ART is controversial but a different management strategy is not required for recurrent endometriomas. Since recurrent endometriomas do not have a worse impact on ART outcome than primary endometriomas, and repeat surgery has a higher risk for complications, conservative management without surgery can be justified.Study Funding/competing Interest(s): No funding or competing interests to declare.Trial Registration Number: None. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
13. Comparison of automated and manual follicle monitoring in an unrestricted population of 100 women undergoing controlled ovarian stimulation for IVF.
- Author
-
Ata, Baris, Seyhan, Ayse, Reinblatt, Shauna Leigh, Shalom-Paz, Einat, Krishnamurthy, Srinivasan, and Tan, Seang Lin
- Subjects
- *
COMPARATIVE studies , *OVARIAN follicle , *DISEASES in women , *FERTILIZATION in vitro , *GONADOTROPIN , *ULTRASONIC imaging , *MEDICAL screening - Abstract
Background: Ovarian response to gonadotrophin stimulation is monitored with serial ultrasound (US) examinations. Sonography-based Automated Volume Count (SonoAVC) is a relatively new three-dimensional (3D) US technology, which automatically generates a set of measurements including the mean follicular diameter (MFD) and a volume-based diameter (d(V)) for each follicle in the ovaries. The present study aimed to assess the applicability and reproducibility of this automated follicle measurement method in an IVF programme.Methods: For this prospective method comparison study, 100 women undergoing US monitoring of a controlled ovarian stimulation cycle were recruited. Each follicle was manually measured by taking the mean of maximal diameters on three orthogonal planes with two-dimensional (2D) US. A 3D volume of each ovary was then captured. The ovarian volumes were later analysed using SonoAVC. The agreement between the two methods for the numbers of follicles and the size of the leading follicle was assessed with the Bland-Altman method. The reproducibility of SonoAVC measurements was assessed with the intraclass correlation coefficient (ICC).Results: Both SonoAVC-generated MFD and d(V)-based follicle counts, as well as the leading follicle diameter, had good agreement with conventional 2D US measurements. SonoAVC measurements had very good reproducibility, with ICC ≥0.8 for most evaluations.Conclusions: Automated follicle monitoring with SonoAVC can replace or be used interchangeably with conventional 2D measurements. Automated follicle monitoring can save time, provide a method of quality control and create opportunities for developing HCG criteria based on follicular volume or for monitoring patients from a distance. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
14. Which is worse? A comparison of ART outcome between women with primary or recurrent endometriomas.
- Author
-
Ata, Baris, Mumusoglu, Sezcan, Aslan, Kiper, Seyhan, Ayse, Kasapoglu, Isil, Avci, Berrin, Urman, Bulent, Bozdag, Gurkan, and Uncu, Gurkan
- Subjects
- *
REPRODUCTIVE technology , *ENDOMETRIOSIS - Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.